120 results
Page 2 of 6
6-K
EX-99.1
ru7nisx
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
6-K
EX-99.1
fqbqj o6h
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
6-K
EX-99.1
9rlmam9y9691
27 May 22
ObsEva Announces Corporate Updates
4:56pm
6-K
2xoo0u741q5dd
27 May 22
ObsEva Announces Corporate Updates
4:56pm
6-K
EX-99.3
punj3xc1mj4tle dt46
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
l230or9gepnah4a2xl8
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.1
f7klpdlsnp4tpp fuhvg
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
6-K
EX-99.1
tw4r0j4kjbghzbr1c
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
6-K
EX-99.1
tjb0z7 jo57n0f1q3
22 Mar 22
Current report (foreign)
7:28am
6-K
EX-99.1
9mkf9mjc fo
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
6-K
EX-99.1
2rbz52t1m c52l6hz
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
EX-99.1
g3yyapxu2u03jfdlb9n
4 Feb 22
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral
4:37pm
6-K
EX-99.1
2uhf avh8oe
1 Feb 22
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
6:05am
6-K
EX-99.1
xsu4rl4dtwja7as5jzwy
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K
acokzjauahjerc
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K
EX-99.3
s74n77rhm1s1eoy0xkl2
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm